Table 2.
Overview of clinical trials listing the fraction (%) of studies evaluating pulmonary diseases among all trials or the fraction of specific lung diseases, when only trials on pulmonary diseases were included.
| Year of Publication | Number of Trials Analysed | % of (Specific) Pulmonary Diseases in the Analysed Trials | Reference |
|---|---|---|---|
| 2015 | 339 (all indications) | 3 (pulmonary diseases) | [74] |
| 2015 | 516 (all indications) | 6 (pulmonary diseases) | [6] |
| 2016 | 493 (all indications) | 5 (pulmonary diseases) | [75] |
| 2017 | 109 (all indications) | 10 (pulmonary diseases) | [76] |
| 2019 | 49 (pulmonary diseases) | BPD (37), IPF (14), ARDS (29), asthma (4), COPD (4) | [77] |
| 2020 | 767 (all indications) | 7 (pulmonary diseases) | [78] |
| 2020 | 62 (COVID-19) | N.a. | [79] |
| 2020 | 73 (ARDS, COVID-19) | ARDS (57), COVID-19 (22), ARDS/COVID-19 (21) | [1] |
| 2020 | 16 (COVID-19) | N.a. | [80] |
| 2020 | 83 (pulmonary diseases) | COVID-19 (47), pulmonary fibrosis (10), ARDS (10), asthma (2), COPD (7) | [81] |
| 2020 | 68 (pulmonary diseases) | COVID-19 (45), ARDS (15), COPD (15), asthma (3), IPF (9) | [39] |